Evidence map›Paper›PMID 33683511›Full record

ArticleBiotechnology letters2021

Cell engineering method using fluorogenic oligonucleotide signaling probes and flow cytometry.

Kambiz Shekdar, Jessica Langer, Srinivasan Venkatachalan, Lori Schmid, Jonathan Anobile, Purvi Shah, Amy Lancaster, Olga Babich, Olga Dedova, Dennis Sawchuk

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biotechnology letters, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Kambiz ShekdarChromocell Corporation, North Brunswick, NJ, USA. kambiz.shekdar@secondcellbio.com.ORCID http://orcid.org/0000-0002-4071-0475
Jessica LangerChromocell Corporation, North Brunswick, NJ, USA.
Srinivasan VenkatachalanChromocell Corporation, North Brunswick, NJ, USA.
Lori SchmidChromocell Corporation, North Brunswick, NJ, USA.
Jonathan AnobileChromocell Corporation, North Brunswick, NJ, USA.
Purvi ShahChromocell Corporation, North Brunswick, NJ, USA.
Amy LancasterChromocell Corporation, North Brunswick, NJ, USA.
Olga BabichChromocell Corporation, North Brunswick, NJ, USA.
Olga DedovaChromocell Corporation, North Brunswick, NJ, USA.
Dennis SawchukChromocell Corporation, North Brunswick, NJ, USA.
Chromocell (United States) · USPeptcell (United Kingdom) · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveChromovert® Technology is presented as a new cell engineering technology to detect and purify living cells based on gene expression.

methodsThe technology utilizes fluorogenic oligonucleotide signaling probes and flow cytometry to detect and isolate individual living cells expressing one or more transfected or endogenously-expressed genes.

resultsResults for production of cell lines expressing a diversity of ion channel and membrane proteins are presented, including heteromultimeric epithelial sodium channel (αβγ-ENaC), sodium voltage-gated ion channel 1.7 (NaV1.7-αβ1β2), four unique γ-aminobutyric acid A (GABA

conclusionsChromovert technology is provided as a research tool for use to enrich and isolate cells engineered to express one or more desired genes.

Indexed as

Oligonucleotide ProbesAnimalsCell EngineeringCell LineFlow CytometryFluorescenceGenetic EngineeringHumansIon ChannelsNucleic Acid ConformationNucleic Acid HybridizationReceptors, G-Protein-CoupledIon ChannelsOligonucleotide ProbesReceptors, G-Protein-CoupledCell engineeringCell lineFlow cytometryFluorescence-activated cell sorting (FACS)Genetic engineeringGPCRIon channel

Identifiers

PMID33683511
PMCPMC7937778
OpenAlexW3134583738

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.